Aprilbio Co. Ltd.
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is h… Read more
Aprilbio Co. Ltd. (397030) - Total Liabilities
Latest total liabilities as of September 2025: ₩6.62 Billion KRW
Based on the latest financial reports, Aprilbio Co. Ltd. (397030) has total liabilities worth ₩6.62 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aprilbio Co. Ltd. - Total Liabilities Trend (2020–2024)
This chart illustrates how Aprilbio Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aprilbio Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Aprilbio Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sumitomo Osaka Cement Co. Ltd
F:SU2
|
Germany | €162.87 Billion |
|
Zhejiang Construction Investment Group Co Ltd
SHE:002761
|
China | CN¥111.45 Billion |
|
Xiamen Anne Corp Ltd
SHE:002235
|
China | CN¥435.96 Million |
|
Shenzhen Newway Photomask Making Co. Ltd. A
SHG:688401
|
China | CN¥1.49 Billion |
|
Almirall S.A
PINK:LBTSF
|
USA | $844.82 Million |
|
Hangzhou Steam Turbine
SHE:200771
|
China | HK$7.62 Billion |
|
Equitas Small Finance Bank Limited
NSE:EQUITASBNK
|
India | ₹-60.73 Billion |
|
Wereldhave N.V
PINK:WRDEF
|
USA | $1.30 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Aprilbio Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aprilbio Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aprilbio Co. Ltd. (2020–2024)
The table below shows the annual total liabilities of Aprilbio Co. Ltd. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩8.61 Billion | -60.78% |
| 2023-12-31 | ₩21.95 Billion | +1053.64% |
| 2022-12-31 | ₩1.90 Billion | -54.81% |
| 2021-12-31 | ₩4.21 Billion | -87.31% |
| 2020-12-31 | ₩33.19 Billion | -- |